Last reviewed · How we verify
Daily rifapentine and isoniazid for 4 weeks
Daily rifapentine and isoniazid for 4 weeks is a Small molecule drug developed by The Aurum Institute NPC. It is currently FDA-approved.
At a glance
| Generic name | Daily rifapentine and isoniazid for 4 weeks |
|---|---|
| Sponsor | The Aurum Institute NPC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts (PHASE3)
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (PHASE1, PHASE2)
- Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients (PHASE4)
- Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (PHASE1, PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daily rifapentine and isoniazid for 4 weeks CI brief — competitive landscape report
- Daily rifapentine and isoniazid for 4 weeks updates RSS · CI watch RSS
- The Aurum Institute NPC portfolio CI
Frequently asked questions about Daily rifapentine and isoniazid for 4 weeks
What is Daily rifapentine and isoniazid for 4 weeks?
Daily rifapentine and isoniazid for 4 weeks is a Small molecule drug developed by The Aurum Institute NPC.
Who makes Daily rifapentine and isoniazid for 4 weeks?
Daily rifapentine and isoniazid for 4 weeks is developed and marketed by The Aurum Institute NPC (see full The Aurum Institute NPC pipeline at /company/the-aurum-institute-npc).
What development phase is Daily rifapentine and isoniazid for 4 weeks in?
Daily rifapentine and isoniazid for 4 weeks is FDA-approved (marketed).